Orexigen Therapeutics (NASDAQ:OREX) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. The business earned $5 million during the quarter, compared to analyst estimates of $7.78 million. Orexigen Therapeutics’s revenue for the quarter was up 16.3% compared to the same quarter last year. Analysts anticipate that Orexigen Therapeutics, Inc. will post ($0.50) EPS for the current fiscal year.
OREX has been the subject of several recent analyst reports. Zacks Investment Research reaffirmed a “buy” rating and set a $2.25 price objective on shares of Orexigen Therapeutics in a research report on Sunday, January 31st. Leerink Swann cut shares of Orexigen Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $4.50 to $2.00 in a research report on Tuesday, February 23rd. RBC Capital cut shares of Orexigen Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $5.00 to $1.00 in a research report on Monday, February 29th. JPMorgan Chase & Co. cut shares of Orexigen Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, February 29th. Finally, Piper Jaffray decreased their price objective on shares of Orexigen Therapeutics from $11.00 to $5.00 and set an “overweight” rating for the company in a research report on Monday, February 29th. One analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $2.61.
Orexigen Therapeutics, Inc (NASDAQ:OREX) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company’s product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
